Evoke Pharma, Inc., a health care company headquartered in Solana Beach, California, continues to make strides in the pharmaceutical industry with its focus on developing, manufacturing, and marketing pharmaceutical products. The company is particularly noted for its gastrointestinal product designed to treat diabetic gastroparesis, a condition that affects the digestive system of individuals with diabetes.
As of November 11, 2025, Evoke Pharma’s stock closed at $10.68 on the Nasdaq, where it has been publicly traded since its initial public offering on September 25, 2013. The company’s stock has experienced significant volatility over the past year, with a 52-week high of $10.79 recorded on November 3, 2025, and a 52-week low of $1.94 on April 14, 2025. This fluctuation reflects the dynamic nature of the pharmaceutical sector and the challenges faced by companies in this industry.
Evoke Pharma’s market capitalization stands at $22,330,000 USD, indicating its valuation in the market. However, the company’s price-to-earnings ratio is currently at -5.26, suggesting that it has not yet achieved profitability. This negative ratio is not uncommon in the pharmaceutical industry, where companies often invest heavily in research and development before realizing returns.
The company’s primary focus remains on its flagship product for diabetic gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction. This product aims to improve the quality of life for patients by alleviating symptoms associated with the disease, such as nausea, vomiting, and abdominal pain.
Evoke Pharma conducts its operations primarily within the United States, leveraging its strategic location in California to access a robust network of research facilities and healthcare professionals. The company’s commitment to innovation and patient care is evident in its ongoing efforts to enhance its product offerings and expand its reach within the healthcare market.
For more information about Evoke Pharma, Inc., stakeholders and interested parties can visit the company’s official website at www.evokepharma.com . The company continues to focus on its mission to provide effective treatments for gastrointestinal disorders, with a particular emphasis on addressing the needs of patients with diabetic gastroparesis.
